These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 16163171)

  • 21. PET and PET/CT in management of the lymphomas.
    Podoloff DA; Macapinlac HA
    Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of FDG-PET in malignant lymphoma.
    Becherer A; Jaeger U; Szabo M; Kletter K
    Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
    Pakos EE; Fotopoulos AD; Ioannidis JP
    J Nucl Med; 2005 Jun; 46(6):958-63. PubMed ID: 15937306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
    Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of FDG-PET in staging of lymphoma and evaluation of therapeutic efficiency].
    Zhou LL; Wang C; Zhao JH; Yan SK; Gao YR; Cai Q; Jiang JL; Wan LP; Yang J; Wei J; Zhao M; Bai HT
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):233-6. PubMed ID: 19731822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG-PET/CT in lymphoma.
    Juweid ME
    Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
    Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
    J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of early response assessment in lymphoma with FDG-PET.
    MacManus MP; Seymour JF; Hicks RJ
    Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET/computed tomography and lymphoma.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma.
    Lin P; Chu J; Kneebone A; Moylan E; Jalaludin B; Pocock N; Kiat H; Rosenfeld D
    Intern Med J; 2005 Feb; 35(2):91-6. PubMed ID: 15705137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET and restaging of malignant lymphoma including residual masses and relapse.
    Reske SN
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S89-96. PubMed ID: 12748829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorine-18-fluorodeoxyglucose positron emission tomography metabolic imaging in patients with lymphoma.
    Huić D; Dodig D
    Croat Med J; 2002 Oct; 43(5):541-5. PubMed ID: 12402392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
    Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
    Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma.
    Okada M; Sato N; Ishii K; Matsumura K; Hosono M; Murakami T
    Radiographics; 2010; 30(4):939-57. PubMed ID: 20631361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
    Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
    Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of PET in lymphoma.
    Schwaiger M; Wieder H
    Chang Gung Med J; 2005 May; 28(5):315-25. PubMed ID: 16086546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.